{"id":1432,"date":"2024-07-25T09:26:36","date_gmt":"2024-07-25T01:26:36","guid":{"rendered":"https:\/\/flcube.com\/?p=1432"},"modified":"2024-11-04T21:10:57","modified_gmt":"2024-11-04T13:10:57","slug":"oneness-biotech-and-microbio-partner-with-cr-double-crane-for-fespixon-commercialization-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=1432","title":{"rendered":"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China"},"content":{"rendered":"\n<p>Taiwan&#8217;s Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal with China mainland firm CR Double-Crane. The agreement grants CR Double-Crane a 20-year exclusive license to commercialize Fespixon (ON101), a novel etiology-driven solution designed to regulate macrophages and enhance tissue repair, within the Chinese market. This breakthrough therapy is intended for wound care, with a specific focus on diabetic foot ulcers (DFUs), a segment that represents a significant market opportunity in China, where approximately 8.3 million patients suffer from DFUs .<\/p>\n\n\n\n<p>Fespixon, classified as a Category 1 innovative drug, has demonstrated impressive results in clinical trials, showing a 29.2% increase in sales in the second quarter of 2024, reaching \u20ac3.303 billion (USD 3.58 billion). Oneness Biotech has high hopes for the drug&#8217;s inclusion in China&#8217;s National Reimbursement Drug List (NRDL), which would significantly broaden patient access .<\/p>\n\n\n\n<p>Under the terms of the agreement, CR Double-Crane will make an upfront payment of up to USD 34 million to Microbio (Shanghai), with potential sales milestone payments of USD 13.6 million for each tranche of RMB 1 billion net sales achieved. If annual net sales reach RMB 5 billion, the total payments could exceed USD 100 million .<\/p>\n\n\n\n<p>This strategic partnership not only underscores the potential of Fespixon in the Chinese market but also highlights the growing interest in innovative therapies for DFUs, which have traditionally been challenging to treat effectively. Oneness Biotech and Microbio (Shanghai) are committed to advancing wound care solutions, and this deal is expected to pave the way for further collaborations and market expansions in the future . &#8211; <a href=\"https:\/\/flcube.com\">Fineline.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Taiwan&#8217;s Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1085,471],"class_list":["post-1432","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-microbio","tag-oneness-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Taiwan&#039;s Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal with China mainland firm CR Double-Crane. The agreement grants CR Double-Crane a 20-year exclusive license to commercialize Fespixon (ON101), a novel etiology-driven solution designed to regulate macrophages and enhance tissue repair, within the Chinese market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=1432\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=1432\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-25T01:26:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-04T13:10:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1432#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1432\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China\",\"datePublished\":\"2024-07-25T01:26:36+00:00\",\"dateModified\":\"2024-11-04T13:10:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1432\"},\"wordCount\":268,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Microbio\",\"Oneness Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1432#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1432\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=1432\",\"name\":\"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-07-25T01:26:36+00:00\",\"dateModified\":\"2024-11-04T13:10:57+00:00\",\"description\":\"Taiwan's Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal with China mainland firm CR Double-Crane. The agreement grants CR Double-Crane a 20-year exclusive license to commercialize Fespixon (ON101), a novel etiology-driven solution designed to regulate macrophages and enhance tissue repair, within the Chinese market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1432#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1432\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1432#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China - Insight, China&#039;s Pharmaceutical Industry","description":"Taiwan's Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal with China mainland firm CR Double-Crane. The agreement grants CR Double-Crane a 20-year exclusive license to commercialize Fespixon (ON101), a novel etiology-driven solution designed to regulate macrophages and enhance tissue repair, within the Chinese market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=1432","og_locale":"en_US","og_type":"article","og_title":"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=1432","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-07-25T01:26:36+00:00","article_modified_time":"2024-11-04T13:10:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=1432#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=1432"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China","datePublished":"2024-07-25T01:26:36+00:00","dateModified":"2024-11-04T13:10:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=1432"},"wordCount":268,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Microbio","Oneness Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=1432#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=1432","url":"https:\/\/flcube.com\/?p=1432","name":"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-07-25T01:26:36+00:00","dateModified":"2024-11-04T13:10:57+00:00","description":"Taiwan's Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal with China mainland firm CR Double-Crane. The agreement grants CR Double-Crane a 20-year exclusive license to commercialize Fespixon (ON101), a novel etiology-driven solution designed to regulate macrophages and enhance tissue repair, within the Chinese market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=1432#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=1432"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=1432#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1432"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1432\/revisions"}],"predecessor-version":[{"id":4903,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1432\/revisions\/4903"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}